Abstract
The CXC chemokine receptor 2 (CXCR2) has attracted a considerable amount of attention as a target for therapeutic intervention due the key role this receptor plays in a number of inflammatory disorders. Over the past decade, several classes of potent, selective CXCR2 receptor antagonists have been developed as potential anti-inflammatory agents. These small-molecule chemokine receptor antagonists have demonstrated the ability to inhibit CXCR2-mediated recruitment of inflammatory cells in vitro as well as shown efficacy in vivo in various animal models of inflammation. In addition, several of the most advanced CXCR2 receptor antagonists have recently demonstrated promising proof-of-activity results in early human clinical trials. This review details the discovery and development of the 3,4-diaminocyclobut-3- ene-1,2-dione-based CXCR2 receptor antagonist class including SCH 527123 which is currently in mid-stage clinical evaluation. The medicinal chemistry efforts leading to the discovery of SCH 527123, the in vitro and in vivo pharmacology for this compound, and an overview of the clinical evaluation of SCH 527123 will also be discussed.
Keywords: CXCR2, 3, 4-diaminocyclobut-3-ene-1, 2-dione, SCH 527123
Current Topics in Medicinal Chemistry
Title: Discovery of 3,4-Diaminocyclobut-3-ene-1,2-dione-Based CXCR2 Receptor Antagonists for the Treatment of Inflammatory Disorders
Volume: 10 Issue: 13
Author(s): Michael P. Dwyer and Purakattle Biju
Affiliation:
Keywords: CXCR2, 3, 4-diaminocyclobut-3-ene-1, 2-dione, SCH 527123
Abstract: The CXC chemokine receptor 2 (CXCR2) has attracted a considerable amount of attention as a target for therapeutic intervention due the key role this receptor plays in a number of inflammatory disorders. Over the past decade, several classes of potent, selective CXCR2 receptor antagonists have been developed as potential anti-inflammatory agents. These small-molecule chemokine receptor antagonists have demonstrated the ability to inhibit CXCR2-mediated recruitment of inflammatory cells in vitro as well as shown efficacy in vivo in various animal models of inflammation. In addition, several of the most advanced CXCR2 receptor antagonists have recently demonstrated promising proof-of-activity results in early human clinical trials. This review details the discovery and development of the 3,4-diaminocyclobut-3- ene-1,2-dione-based CXCR2 receptor antagonist class including SCH 527123 which is currently in mid-stage clinical evaluation. The medicinal chemistry efforts leading to the discovery of SCH 527123, the in vitro and in vivo pharmacology for this compound, and an overview of the clinical evaluation of SCH 527123 will also be discussed.
Export Options
About this article
Cite this article as:
P. Dwyer Michael and Biju Purakattle, Discovery of 3,4-Diaminocyclobut-3-ene-1,2-dione-Based CXCR2 Receptor Antagonists for the Treatment of Inflammatory Disorders, Current Topics in Medicinal Chemistry 2010; 10 (13) . https://dx.doi.org/10.2174/156802610791561246
DOI https://dx.doi.org/10.2174/156802610791561246 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Redox Homeostasis and Epigenetics in Non-alcoholic Fatty Liver Disease (NAFLD)
Current Pharmaceutical Design β-lactam Structured, 4-(4-(Methylsulfonyl)phenyl)-1-pentyl-3-phenoxyazetidin-2-one: Selectively Targets Cancerous B Lymphocyte Mitochondria
Anti-Cancer Agents in Medicinal Chemistry Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Current Medicinal Chemistry Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Current Drug Targets Study of 5-Fluorouracil Loaded Chitosan Nanoparticles for Treatment of Skin Cancer
Recent Patents on Nanotechnology Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress
Current Pharmaceutical Biotechnology Immuno-Isolation in Cancer Gene Therapy
Current Gene Therapy A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity
Current Genomics In Vitro Regulatory Effect of Epididymal Serpin CRES on Protease Activity of Proprotein Convertase PC4/PCSK4
Current Molecular Medicine Endothelial Cells in Inflammation and Angiogenesis
Current Drug Targets - Inflammation & Allergy Immune Therapy in Pancreatic Cancer: Now and the Future?
Reviews on Recent Clinical Trials The Importance of Stereochemistry on the Actions of Vitamin D
Current Topics in Medicinal Chemistry Syntheses and Antitumor Activities of Potent Inhibitors of Ribonucleotide Reductase: 3-Amino-4-Methylpyridine-2-Carboxaldehyde-Thiosemicarbazone (3-Amp), 3-Amino-Pyridine-2-Carboxaldehyde-Thiosemicarbazone (3-Ap) and its Water-Soluble Prodrugs
Current Medicinal Chemistry The Influence of Wuzhi Capsule on the Pharmacokinetics of Cyclophosphamide
Recent Patents on Anti-Cancer Drug Discovery Long-Term Immunovirogical Effect and Tolerability of a Maraviroc- Containing Regimen in Routine Clinical Practice
Current HIV Research Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward
Anti-Cancer Agents in Medicinal Chemistry Current Status and Perspectives in Peptide Receptor Radiation Therapy
Current Pharmaceutical Design Growth Factors, Cytokines and Dendritic Cell Development
Current Pharmaceutical Design Effects of Natural Compounds on Xenopus Embryogenesis: A Potential Read Out for Functional Drug Discovery Targeting Wnt/β-catenin Signaling
Current Topics in Medicinal Chemistry Juglone Exerts Cytotoxic, Anti-proliferative and Anti-invasive Effects on Glioblastoma Multiforme in a Cell Culture Model
Anti-Cancer Agents in Medicinal Chemistry